Pharmaceutical Executive-09-01-2012

Issue PDF
Pharmaceutical Executive

September 01, 2012

Busting the Tape

Pharmaceutical Executive
Features

September 01, 2012

Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.

Pharmaceutical Executive
Column

September 01, 2012

In the digital age, physicians don't call the shots when it comes to healthcare guidance, writes Al Topin.

Pharmaceutical Executive
Column

September 01, 2012

Europe's fiscal crisis is becoming a new rallying cry for patient groups-but regional unity is still elusive.

Pharmaceutical Executive

Bending the cost curve back to valuing the cycle of life.

Pharmaceutical Executive
Column

September 01, 2012

Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. Patient voices are increasing in volume, along with their roles in treatment decisions.

Pharmaceutical Executive

"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."

Pharmaceutical Executive
Column

September 01, 2012

Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.

Pharmaceutical Executive
From the Editor

September 01, 2012

Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.

Pharmaceutical Executive

High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell.

Pharmaceutical Executive

There is much talk today about "open innovation" in business and research forums-but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? Does it signal a change in the way pharmaceutical companies approach research and innovation?